From Discovery To Development To Delivery

AZBio is committed to building a top-tier life science industry in Arizona.

Arizona’s bioscience industry is growing rapidly and reached nearly 30,000 jobs spanning 2,160 business establishments in 2018. Industry employment has grown by 15 percent since 2016—twice the growth rate of the nation—with each of the five major subsectors adding jobs during the period. Arizona’s universities conducted nearly $580 million in R&D activities in bioscience-related fields in 2018, fueled in part by steadily increasing NIH awards to Arizona institutions since 2016. Venture capital investments in Arizona bioscience companies increased in 2019, and during the 2016-19 period totaled $349 million. Arizona inventors have been awarded 2,178 bioscience-related patents since 2016, among the second quintile of states in patent activity.

IN THE LOOP

AZBio In The Loop is your opportunity to stay up to date on what is happening across Arizona's Life Science and Healthcare Community.

Subscribe

AZBio Members Are Making LIFE Bettter

AZBio Members discover, develop, and deliver life-saving and life-changing innovations.

Premiere Supporters

Leadership Supporters

Sustaining Members

Get Connected With Arizona's Bioindustry

A key component in Arizona’s life science ecosystem, the Arizona Bioindustry Association (AZBio) is the only statewide organization exclusively focused on Arizona’s bioscience industry.  AZBio membership includes patient advocacy organizations, life science innovators, educators, healthcare partners and leading business organizations. AZBio is the statewide affiliate of the Biotechnology Innovation Organization (BIO) and works in partnership with AdvaMed, MDMA, and PhRMA to advance innovation and to ensure that the value delivered from life-changing and life-saving innovation benefits people in Arizona and around the world.

 

Success Stories – Good News from Arizona’s BioIndustry

Pfizer and BioNTech Announce Early Positive Data from Ongiing Phase 1/2 Study of mRNA-based Vaccine Candidate Against SARS-COV-2

In an ongoing U.S. Phase 1/2 placebo-controlled, observer-blinded clinical trial, nucleoside-modified messenger RNA vaccine candidate (BNT162b1) expressing the SARS-CoV-2 receptor binding domain (RBD) is being evaluated in 45 subjects At day 28 (7 days after dose 2), all subjects who received 10 or 30 µg of BNT162b1 had significantly elevated RBD-binding IgG antibodies with geometric […]

Cancer Prevention Pharmaceuticals Submits New Drug Application to the FDA for CPP-1X/sul for Treatment of Familial Adenomatous Polyposis

Company seeks accelerated approval for cancer drug  TUCSON, Arizona, June 29, 2020 – Cancer Prevention Pharmaceuticals, Inc. (CPP), a private biotech company developing novel therapeutics to prevent cancer and other diseases, announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking accelerated approval for CPP-1X/sul for […]

Gilead Announces Pricing for Remdesivir in Open Letter

According to Daniel O’Day, Chairman & CEO, Gilead Sciences,  “In the U.S., the same government price of $390 per vial will apply. Because of the way the U.S. system is set up and the discounts that government healthcare programs expect, the price for U.S. private insurance companies, will be $520 per vial. At the level […]

AZBio Builds Relationships With Partners Across The Country

Partner Opportunities for AZBio Members

  • Click the image to learn more